LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Urinalysis Market Valued at USD 2 Billion by 2022

By LabMedica International staff writers
Posted on 26 Mar 2019
The global urinalysis market is expected to grow at a CAGR of 7.5% from 2018 to 2022 to reach a value of USD 2.14 billion by 2022, driven by a large base of the target population and increasing demand for urinalysis due to unmet clinical needs in the under-developed regions globally. Additionally, the introduction of highly advanced diagnostic tools and rising demand for cost-effective solutions will further fuel the robust growth of the global urinalysis market.

These are the latest findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company.

Urinalysis acts as a vital diagnostic tool for the analysis and management of target diseases such as urinary tract infection (UTI) disorders, kidney diseases, and diabetes. The growing prevalence of these target diseases is expected to drive the market demand for urinalysis in the coming years, providing significant opportunities for market players to invest in research and development. Moreover, changing lifestyles and varying food are expected to fuel the demand for urinalysis across the world over the coming years. Also, the increasing adoption of wireless technology for communication purposes, coupled with the development of miniaturized PoC urinalysis instruments, are further expected to advance the market growth in the coming years.

However, the complete absence of adequate healthcare infrastructure in the underdeveloped economies worldwide is likely to limit the market growth to some extent. Additionally, the non-availability of the latest diagnostic tools in the developing economies globally is also significantly hampering market growth. Nevertheless, the development of advanced and cost-effective techniques for performing fast and highly precise diagnosis, coupled with easy-to-use solutions for catering to the unmet clinical needs in the developing as well as underdeveloped economies, are expected to drive the growth of the global urinalysis market over the coming years.

Based on product type, the instruments segment is expected to record a significant growth during the forecast period due to the development of novel products such as automated urine sediment analyzers, microscopic urine analyzers and fully automated urine strip readers.

Geographically, the North American urinalysis market has witnessed major growth in recent years due to increasing implementation of the latest technologies in the medicine & pharmaceutical sectors, development of automated urine sediment analyzers such as digital flow morphology and fluorescence flow cytometry, and a well-established infrastructure present in the region.

Geographically, Asia-Pacific will hold a major share in the global urinalysis market and record a massive growth during the forecast period, led by countries such as India, China and Singapore, the rising penetration of advanced urine analyzers, increasing healthcare expenditure and significant investments by leading industry players for capitalizing on the potential growth opportunities in the region.

Related Links:
Grand View Research

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more